CA2453662A1 - Modification de domaines humains variables - Google Patents

Modification de domaines humains variables Download PDF

Info

Publication number
CA2453662A1
CA2453662A1 CA002453662A CA2453662A CA2453662A1 CA 2453662 A1 CA2453662 A1 CA 2453662A1 CA 002453662 A CA002453662 A CA 002453662A CA 2453662 A CA2453662 A CA 2453662A CA 2453662 A1 CA2453662 A1 CA 2453662A1
Authority
CA
Canada
Prior art keywords
domain
amino acid
subclass
nucleic acid
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CA002453662A
Other languages
English (en)
Inventor
Stefan Ewert
Thomas Huber
Annemarie Honegger
Andreas Plueckthun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2453662A1 publication Critical patent/CA2453662A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un procédé d'optimisation de constructions variables lourde (V¿H?) et légère (V¿L?) d'immunoglobine humaine isolée.
CA002453662A 2001-07-19 2002-07-19 Modification de domaines humains variables Withdrawn CA2453662A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01116756.6 2001-07-19
EP01116756 2001-07-19
PCT/EP2002/008094 WO2003008451A2 (fr) 2001-07-19 2002-07-19 Modification de domaines humains variables

Publications (1)

Publication Number Publication Date
CA2453662A1 true CA2453662A1 (fr) 2003-01-30

Family

ID=8177996

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002453662A Withdrawn CA2453662A1 (fr) 2001-07-19 2002-07-19 Modification de domaines humains variables

Country Status (5)

Country Link
US (1) US20060127893A1 (fr)
EP (1) EP1406931A2 (fr)
JP (1) JP4355571B2 (fr)
CA (1) CA2453662A1 (fr)
WO (1) WO2003008451A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1691763A4 (fr) * 2003-12-12 2008-03-12 Genencor Int Molecules cab
JP5142707B2 (ja) * 2005-02-08 2013-02-13 一般財団法人化学及血清療法研究所 抗体の改良方法
CA2653661A1 (fr) * 2006-05-31 2007-12-06 Astellas Pharma Inc. Anticorps d'osteopontine anti-humains humanises
EP2118344B1 (fr) 2007-02-12 2014-07-23 Proteonova, Inc. Generation d'une bibliotheque de polypeptides aleatoires solubles lies a l'arnm
RU2009137582A (ru) * 2007-03-12 2011-04-20 Эсбатек Аг (Ch) Инженерия и оптимизация одноцепочечных антител на основе последовательности
BRPI0813645A2 (pt) * 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
EP2164961B1 (fr) * 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Ingénierie basée sur les séquences et optimisation d'anticorps monocaténaires
AU2010306774A1 (en) 2009-10-14 2012-05-03 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
CA2843158A1 (fr) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Anticorps bispecifiques a fc en tandem
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
CA3002097A1 (fr) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Composes interagissant avec le glycane et methodes d'utilisation
CA3029332A1 (fr) 2016-07-01 2018-01-04 Ludwig Institute For Cancer Research Ltd Procedes et compositions pour l'inhibition du pdgf-cc
WO2018094143A1 (fr) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Composés interagissant avec le glycane et méthodes d'utilisation
WO2018160909A1 (fr) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Composés interagissant avec le glycane et méthodes d'utilisation
US20210221915A1 (en) * 2018-06-08 2021-07-22 Ventana Medical Systems, Inc. Universal or normalized antibody frameworks for improved functionality and manufacturability
WO2025132503A1 (fr) * 2023-12-20 2025-06-26 F. Hoffmann-La Roche Ag Anticorps se liant à ceacam5

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0605522B1 (fr) * 1991-09-23 1999-06-23 Medical Research Council Méthodes de production d'anticorps humanisés
GB9203459D0 (en) * 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions

Also Published As

Publication number Publication date
WO2003008451A3 (fr) 2004-01-29
US20060127893A1 (en) 2006-06-15
JP4355571B2 (ja) 2009-11-04
EP1406931A2 (fr) 2004-04-14
WO2003008451A2 (fr) 2003-01-30
JP2005504526A (ja) 2005-02-17

Similar Documents

Publication Publication Date Title
US20060127893A1 (en) Modification of human variable domains
US10570190B2 (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
Ewert et al. Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach
EP1769000B1 (fr) Polypeptides a expression amelioree
Honegger et al. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains
CN104769113B (zh) 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CN107513104A (zh) 免疫球蛋白结构域的工程改造
WO2008110914A2 (fr) Procédés de production d'anticorps scfv actifs et bibliothèques de ceux-ci
CN113195537A (zh) 抗体文库及方法
Markiv et al. Module based antibody engineering: a novel synthetic REDantibody
HK40051447A (en) Screening and engineering method of super-stable immunoglobulin variable domains and their uses
AU2015202410B2 (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
Seo Development of high throughput screening systems for the efficient production of antibody fragments in Escherichia coli
HK40051447B (zh) 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
Griffin Engineering and characterization of rhizavidin and Fab affinity reagents that possess unique function
Iverson et al. Min Jeong Seo
KR20070052920A (ko) 기능성 Ｆｖ 항체 절편 제조 방법
HK1217712B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1151804B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1071378B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1152320B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1151804A (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Legal Events

Date Code Title Description
EEER Examination request
AZWI Withdrawn application